Despite advances in understanding lung cancer over the past two decades ... where the effects of cancer-causing mutations are countered with drugs. For patients with early-stage NSCLC, targeted ...

daily pill that targets non-small cell lung cancer with RET fusion mutations. Blueprint, which specialises in drugs that target certain mutations, will co-market the drug with Roche’s Genentech ...

If you have non-small-cell lung cancer (NSCLC), your cancer might carry certain changes, or mutations, in your EGFR gene. Those changes make the protein made from this gene act in ways it shouldn’t.

A new study presents a customised treatment strategy using antisense oligonucleotides (ASOs) to target EGFR mutations in ...

Specifically, the new indication covers advanced or metastatic medullary thyroid cancer ... the majority of RET-positive cancers are lung and thyroid tumours, but the mutations are also found ...

Most lung cancer cases are NSCLC. About 32% of NSCLC cases worldwide involve an EGFR mutation. The most common subtype to have an EGFR mutation is adenocarcinoma. Your doctor can do comprehensive ...

The majority of people with advanced EGFR-mutant non-small cell lung cancer (NSCLC) receiving first-line osimertinib ...

Chemoimmunotherapy is currently the preferred first-line treatment option for the majority of patients with advanced non–small cell lung cancer ... receptor 2 mutations, and RET rearrangements ...